Analisis efektivitas biaya pengobatan terapi kelasi besi deferiprone (DFP) dan deferasirox (DFX) tablet pada pasien thalassemia mayor dewasa
DOI: https://doi.org/10.33024/hjk.v19i11.1782
Biaya Pengobatan Deferasirox (DFX) Tablet Kelasi Besi Deferiprone (DFP) Pasien Thalassemia Mayor Dewasa Terapi
Abstract
Background: Thalassemia is a blood disorder caused by abnormalities in hemoglobin. Thalassemia major is a red blood cell disorder that requires high costs because patients need regular blood transfusions and must take iron chelating drugs such as deferiprone and deferasirox throughout their lives to bind serum iron levels.
Purpose: To analyze the cost-effectiveness of iron chelation therapy deferiprone (DFP) and deferasirox (DFX) tablets in adult thalassemia major patients.
Method: Non-experimental research using a retrospective cohort method was conducted from August to December 2024 at Fatmawati Central General Hospital in Jakarta. The sampling technique used consecutive sampling with a total of 56 respondents divided into two groups. The independent variable in this study was the type of iron chelation therapy, while the dependent variable was cost effectiveness. Cost analysis was performed by calculating the total treatment costs for each therapy group using the incremental cost-effectiveness ratio (ICER).
Results: The average total cost of treatment for patients with thalassemia major using deferasirox was Rp10,377,479, which was higher than that of deferiprone at Rp10,055,475. Deferasirox is more effective in reducing serum iron levels, namely 1,786 ng/mL, compared to deferiprone, which only reaches 865 ng/mL. The cost per unit of effectiveness of deferasirox therapy is IDR 5,809, which is lower than deferiprone at IDR 11,629. The incremental cost-effectiveness ratio (ICER) value shows that switching therapy from deferiprone to deferasirox requires an additional cost of Rp349 for each unit of increased effectiveness.
Conclusion: Deferasirox can be the primary choice of iron chelation therapy in adult thalassemia patients, considering its clinical effectiveness and cost efficiency.
Keywords: Adult Thalassemia Major Patients; Deferasirox (DFX) Tablets; Iron Chelation Deferiprone (DFP); Therapy; Treatment Costs.
Pendahuluan: Thalasemia adalah kelainan darah yang disebabkan oleh kelainan pada hemoglobin. Thalasemia mayor merupakan gangguan sel darah merah yang membutuhkan biaya tinggi karena pasien memerlukan darah secara rutin dan sepanjang hidupnya harus mengonsumsi obat pengikat zat besi seperti deferiprone dan deferasirox untuk mengikat kadar Fe serum.
Tujuan: Untuk menganalisis efektivitas biaya pengobatan terapi kelasi besi deferiprone (DFP) dan deferasirox (DFX) tablet pada pasien thalassemia mayor dewasa.
Metode: Penelitian non-eksperimental dengan metode cohort retrospektif, dilaksanakan bulan Agustus-Desember 2024 di Rumah Sakit Umum Pusat Fatmawati Jakarta. Teknik pengambilan sampel menggunakan consequtive sampling dengan jumlah sampel yang digunakan sebanyak 56 responden yang dibagi menjadi dua kelompok. Variabel independen dalam penelitian ini adalah jenis terapi kelasi besi, sedangkan variabel dependen adalah efektivitas biaya. Analisis biaya dengan menghitung total biaya pengobatan pada masing-masing kelompok terapi menggunakan incremental cost-effectiveness ratio (ICER).
Hasil: Rata-rata total biaya pengobatan pasien thalassemia mayor yang menggunakan deferasirox adalah sebesar Rp10,377.479, lebih tinggi dibandingkan dengan deferiprone sebesar Rp10,055.475. Efektivitas deferasirox dalam menurunkan kadar serum besi lebih besar, yaitu 1,786 ng/mL, dibandingkan dengan deferiprone yang hanya mencapai 865 ng/mL. Biaya per unit efektivitas terapi deferasirox adalah Rp5,809, lebih rendah dibandingkan deferiprone sebesar Rp11,629. Nilai incremental cost-effectiveness ratio (ICER) menunjukkan bahwa untuk mengganti terapi dari deferiprone ke deferasirox diperlukan tambahan biaya sebesar Rp349 untuk setiap satuan peningkatan efektivitas.
Simpulan: Deferasirox dapat menjadi pilihan utama terapi kelasi besi pada pasien Thalasemia dewasa dengan mempertimbangkan efektivitas klinis dan efisiensi biaya.
Kata Kunci: Biaya Pengobatan; Deferasirox (DFX) Tablet; Kelasi Besi Deferiprone (DFP); Pasien Thalassemia Mayor Dewasa; Terapi.
Downloads
References
Abidin, R. M., Suwantika, A. A., & Pradipta, I. S. (2024). Analysis Of The Cost Effectiveness Of Oral Iron Cleaning Drugs Between Deferipron And Deferasiroks In Patients With Thalasemia Major At Bhayangkara Kindergarten Hospital. Ii Setukpa Lemdiklat Polri. Asian Journal Of Engineering, Social And Health, 3(1), 173-185.
Cappellini, M. D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., & Alberti, D. (2006). A Phase 3 Study Of Deferasirox (ICL670), A Once-Daily Oral Iron Chelator, In Patients With Β-Thalassemia. Blood, 107(9), 3455-3462.
Chairunnisa, H. G., Sauriasari, R., & Rizkyani, N. A. (2018). Cost-Effectiveness Analysis Of Deferiprone And Deferasirox On Thalassemia Major Patients In Tangerang District Hospital, Indonesia. Journal Of Young Pharmacists, 10(2s), S128.
Chalmers, A. W., & Shammo, J. M. (2016). Evaluation Of A New Tablet Formulation Of Deferasirox To Reduce Chronic Iron Overload After Long-Term Blood Transfusions. Therapeutics And Clinical Risk Management, 201-208.
Cianciulli, P. (2009). Iron Chelation Therapy In Thalassemia Syndromes. Mediterranean Journal Of Hematology And Infectious Diseases, 1(1), E2009034.
Eleftheriou, A., Antoniou, E., Darbà, J., Ascanio, M., Angastiniotis, M., & Farmakis, D. (2022). Estimating The Cost Of Thalassemia Care Across The World: A Thalassemia International Federation Model. Hemoglobin, 46(6), 308-311.
Gatot, D., Amalia, P., Sari, T. T., & Chozie, N. A. (2007). Pendekatan Mutakhir Kelasi Besi Pada Thalassemia. Sari Pediatri, 8(4), 78-84.
Gomber, S., Jain, P., Sharma, S., & Narang, M. (2016). Comparative Efficacy And Safety Of Oral Iron Chelators And Their Novel Combination In Children With Thalassemia. Indian Pediatrics, 53(3), 207-210.
Gustiana, H., Gunantara, T., & Rathomi, H. S. (2020). Kepatuhan Konsumsi Obat Kelasi Besi Dan Kadar Feritin Serum Pasien Talasemia Beta-Mayor Di RSUD Al-Ihsan Bandung. Jurnal Integrasi Kesehatan & Sains, 2(1), 26-30.
Hanifah, M. R. (2020). Gambaran Anak Thalasemia Di Rumah Sakit Umum Daerah Dr. Soediran Mangun Sumarso Wonogiri. ASJN (Aisyiyah Surakarta Journal Of Nursing), 1(1), 16-20.
Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., & Vichinsky, E. (2013). Combined Chelation Therapy With Deferasirox And Deferoxamine In Thalassemia. Blood Cells, Molecules, And Diseases, 50(2), 99-104.
Lazuana, T. (2014). Karakteristik Penderita Thalasemia Yang Dirawat Inap Di RSUP H. Adam Malik Medan Tahun 2011-April 2014. Skripsi, Fakultas Kesehatan Masyarakat Universitas Sumatera Utara.
Li, J., Lin, Y., Li, X., & Zhang, J. (2019). Economic Evaluation Of Chelation Regimens For Β-Thalassemia Major: A Systematic Review. Mediterranean Journal Of Hematology And Infectious Diseases, 11(1), E2019036.
Liansyah, T. M., & Herdata, H. N. (2018). Aspek Klinis Dan Tatalaksana Thalasemia Pada Anak. Jurnal Kedokteran Nanggroe Medika, 1(1), 63-69.
Megawati, F., Suwantara, I. P. T., & Suryani, N. L. S. A. (2020). Perbandingan Tarif Biaya Pasien Diabetes Mellitus Rawat Inap Umum Dan Bpjs Di Salah Satu Rumah Sakit Umum Di Denpasar Periode 2019. Jurnal Ilmiah Medicamento, 6(2).
Pratama, A. R. (2021). Diagnosis And Management Of Thalasemic Cardiomyopathy. Jurnal Kedokteran Syiah Kuala, 21(3).
Priscilla Suyono, E. (2021). Gambaran Kualitas Hidup Penderita Anak Thalasemia Beta Mayor Di Rumah Sakit Pmi Kota Bogor.
Rahayu, Y., Waluyo, E. M. J., & Supardi, S. (2016). Dukungan Keluarga Dalam Kepatuhan Terapi Pada Pasien Thalasemia Di Rumah Sakit Umum Daerah Kabupaten Ciamis Tahun 2015. Mutiara Medika: Jurnal Kedokteran Dan Kesehatan, 16(2), 52-56.
Rujito, L. (2019). Talasemia: Genetik Dasar Dan Pengelolaan Terkini. Universitas Jenderal Soedirman, 10.
Salem, A., Desai, P., & Elgebaly, A. (2023). Efficacy And Safety Of Combined Deferiprone And Deferasirox In Iron-Overloaded Patients: A Systematic Review. Cureus, 15(11).
Sarnianto, P., Fadia, Z., & Gusnellyanti, E. (2013). Pedoman Penerapan Kajian Farmakoekonomi. Kemenkes RI.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Holistik Jurnal Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
